Showing results (1-10 of 21) with videos related to

Sort By:
Pageof 3
Neuroimage. Clinical|July 22, 2025
Fluid and White Matter Suppression contrasts MRI improves Deep Learning detection of Multiple Sclerosis Cortical LesionsPedro M Gordaliza, Jannis Müller, Alessandro Cagol, et al.
Investigative Radiology|May 5, 2022
Fluid and White Matter Suppression: New Sensitive 3 T Magnetic Resonance Imaging Contrasts for Cortical Lesion Detection in Multiple SclerosisJannis Müller, Francesco La Rosa, Jeremy Beaumont, et al.
European Journal of Neurology|August 14, 2023
Comparative analysis of dimethyl fumarate and teriflunomide in relapsing-remitting multiple sclerosisJannis Müller, Sabine Schädelin, Johannes Lorscheider, et al.
JAMA Neurology|October 2, 2023
Harmonizing Definitions for Progression Independent of Relapse Activity in Multiple Sclerosis: A Systematic ReviewJannis Müller, Alessandro Cagol, Johannes Lorscheider, et al.
Cephalalgia : an International Journal of Headache|December 12, 2018
Cortical abnormalities in episodic migraine: A multi-center 3T MRI studyStefano Magon, Arne May, Anne Stankewitz, et al.
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience|October 9, 2015
Morphological Abnormalities of Thalamic Subnuclei in Migraine: A Multicenter MRI Study at 3 TeslaStefano Magon, Arne May, Anne Stankewitz, et al.
Neuroimage. Clinical|August 25, 2022
Brain atrophy measurement over a MRI scanner change in multiple sclerosisTim Sinnecker, Sabine Schädelin, Pascal Benkert, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|April 16, 2025
White Matter Tract Degeneration in Multiple Sclerosis Patients With Progression Independent of Relapse ActivityMario Ocampo-Pineda, Alessandro Cagol, Pascal Benkert, et al.
Journal of Neurology|October 16, 2019
New and enlarging white matter lesions adjacent to the ventricle system and thalamic atrophy are independently associated with lateral ventricular enlargement in multiple sclerosisTim Sinnecker, Esther Ruberte, Sabine Schädelin, et al.
Brain and Behavior|April 30, 2024
Escalating to medium- versus high-efficacy disease modifying therapy after low-efficacy treatment in relapsing remitting multiple sclerosisJannis Müller, Izanne Roos, Tomas Kalincik, et al.
Pageof 3